Abstract
purpose. To determine the efficacy of lysostaphin treatment of
methicillin-sensitive and methicillin-resistant Staphylococcus
aureus (MRSA) keratitis in a rabbit model.
methods. The sensitivity to lysostaphin and vancomycin were compared for 34 MRSA
and 12 methicillin-sensitive strains. Methicillin-resistant S.
aureus strain 301 (MRSA 301) or a methicillin-sensitive strain
of low virulence, ISP546, was intrastromally injected into rabbit
corneas. Rabbit eyes were treated topically every 30 minutes from 4 to
9 or 10 to 15 hours postinfection with 0.28% lysostaphin or 5.0%
vancomycin. Rabbits were killed and corneas were excised and cultured
to determine the number of colony forming units (CFU) per cornea.
results. Ninety percent minimal inhibitory concentrations were at least 19-fold
lower for lysostaphin than for vancomycin. With early therapy (4–9
hours postinfection) lysostaphin sterilized all MRSA 301–infected
corneas, whereas untreated corneas contained 6.52 log CFU/cornea
(P ≤ 0.0001). Corneas infected with MRSA 301 and
treated similarly with vancomycin retained 2.3 ± 0.85 log
CFU/cornea, and none were sterile. When therapy was begun later (10–15
hours postinfection) the residual bacteria in lysostaphin-treated eyes
were significantly less numerous than in vancomycin-treated eyes
(0.58 ± 0.34 vs. 5.83 ± 0.16 log CFU/cornea, respectively; P ≤ 0.0001). Three experiments were performed to
demonstrate that lysostaphin penetrated the cornea to kill bacteria in
vivo; lysostaphin-treated eyes were found to recover from infection,
bacteria that did not cause epithelial defects (ISP546) were
susceptible to lysostaphin, and inhibition of lysostaphin when
harvesting corneas did not alter the observed therapeutic values of
lysostaphin.
conclusions. Lysostaphin is very effective in treating keratitis mediated by
methicillin-sensitive or methicillin-resistant S.
aureus.
In most populations of the United States,
Staphylococcus
aureus is a leading cause of bacterial keratitis, especially among
individuals with a previously compromised cornea.
1 2 3 4 Patients with epithelial trauma caused by contact lens wear or foreign
bodies are more susceptible to
Staphylococcus keratitis.
5 6 Staphylococcus adheres to protein
deposits on contact lenses, permitting bacteria to come in contact with
the corneal surface.
7 8 Tissue damage during
Staphylococcus keratitis results from the action of
bacterial products
9 and from the host inflammatory
response to infection.
10 Staphylococcus keratitis can result in irreversible corneal scarring, resulting in
loss of visual acuity or in blindness.
5
Topical cefazolin, often used in combination with an aminoglycoside, or
a fluoroquinolone (ciprofloxacin or ofloxacin) are the antibiotics most
often prescribed for treating
Staphylococcus keratitis.
5 11 12 13 Topical antibiotic drops are applied as
frequently as every 15 to 30 minutes for 48 hours or longer.
Methicillin-resistant
Staphylococcus aureus (MRSA) strains
have been treated successfully with ciprofloxacin
14 ;
however, during the 1990s the susceptibility of MRSA strains to
fluoroquinolones declined rapidly. Less than half of the current MRSA
isolates remain susceptible to ciprofloxacin or
ofloxacin.
15 16 17 18 19 The increasing incidence of
fluoroquinolone-resistant MRSA strains has resulted in the more
frequent use of vancomycin therapy for most MRSA
infections.
15 16 20 21 22 23 However, vancomycin is a
slow-acting antibiotic that has significant side
effects.
20 24 Also of great concern is the recent
emergence of rare mutant MRSA strains not susceptible to
vancomycin.
25 26 27 28 Furthermore, there is concern that
plasmid-borne vancomycin resistance will be transferred from
Enterococcus faecalis to MRSA strains, creating multiple
strains with resistance to essentially all available antibiotics.
Vancomycin resistance has been conjugally transferred under laboratory
conditions from
E. faecalis to MRSA.
29 Hence
the search for new antimicrobial agents is essential.
Lysostaphin, a zinc metalloproteinase extracted from
Staphylococcus simulans, can lyse
S. aureus by
disrupting its peptidoglycan layer.
30 31 The gene for
lysostaphin has been successfully cloned and expressed in
Bacillus sphaericus and
Escherichia
coli.
32 The major substrate for lysostaphin is the
staphylococcal cell wall,
33 specifically the pentaglycine
bridge found in the cell wall of
S.
aureus. 34 35 36 Lysostaphin has a molecular weight of
27 kDa
34 and contains one molecule of zinc per mole of
protein.
36 The enzyme is destroyed by pepsin or trypsin
and inhibited by Hg
2+,
Cu
2+, and Zn
2+ ions.
37
The use of lysostaphin for chemotherapy was proposed over 30 years
ago.
35 37 Lysostaphin purified from
S. simulans was found to be effective in treating experimental staphylococcal
infections in various nonocular animal models
35 38 and was
once used systemically in a human neutropenic patient to treat
staphylococcal abscesses.
39 Lysostaphin was also shown to
be effective in reducing the nasal carriage of
S. aureus in
humans.
34 40 41
Lysostaphin is now being reexamined as an antibacterial therapy because
antibiotic resistance has become prevalent for many
S.
aureus strains.
42 43 44 Lysostaphin, to date, has not
been described in the therapy of ocular infections or in the treatment
of experimental ocular infections.
New Zealand White rabbits (2.0–3.0 kg) were treated and
maintained in accordance with the tenets of the ARVO Statement on the
Use of Animals in Ophthalmic and Vision Research and in strict
accordance with the institutional guidelines and The Guiding Principles
in the Care and Use of Animals (DHEW Publication, NIH 80-23). All
rabbits were anesthetized by subcutaneous injection of a 1:5 mixture of
xylazine (100 mg/ml, Rompum; Miles Laboratories, Shawnee, KS) and
ketamine hydrochloride (100 mg/ml, Ketaset; Bristol Laboratories,
Syracuse, NY). Proparacaine hydrochloride (0.5% Alcaine; Alcon
Laboratories, Fort Worth, TX) was topically applied to each eye before
intrastromal injection.
Lysostaphin (Sigma, St. Louis, MO) was dissolved in sterile
deionized water to a concentration of 2.8 mg/ml (0.28%). Vancomycin
(Vancoled; Lederle Pharmaceuticals, Carolina, Puerto Rico) was
dissolved in sterile deionized water and further diluted 1:4 in
artificial tears (Tears Naturale Free; Alcon, Humacao, Puerto Rico) to
a final concentration of 50 mg/ml (5.0%), the concentration
recommended for clinical use. The pH of the vancomycin solution was
adjusted to 6.5 with HCl before diluting in artificial tears. All
antibiotics were prepared immediately before use and kept at 0 to
4°C.
Evidence of In Situ Killing of S. aureus